JJP-1008 as a Nov­el Check­point Inhibitor

JJP Bio­log­ics is a Pol­ish biotech­nol­o­gy com­pa­ny devel­op­ing nov­el bio­log­ics for the treat­ment of a range of dis­ease indi­ca­tions. We have mul­ti­ple (pre)clinical pro­grams that we plan to devel­op until clin­i­cal proof of con­cept. JJP-1008 is a pio­neer­ing human­ized and sta­bi­lized IgG4‑κ mon­o­clon­al anti­body tar­get­ing CD270. 

High HVEM expres­sion on tumors cor­re­lates with poor prog­no­sis and an immuno­sup­pres­sive tumor microen­vi­ron­ment, mak­ing it an ide­al tar­get for immuno-oncol­o­gy inter­ven­tions. Tumors, includ­ing melanoma, breast, lung and colon can­cers, exploit CD270 sig­nal­ing path­ways to escape immune attack, lead­ing to dis­ease pro­gres­sion and resis­tance to exist­ing immunotherapies. 

Through our deep mech­a­nis­tic insights, we engi­neered JJP-1008 to offer a much-need­ed nov­el treat­ment option for patients who do not respond to cur­rent PD‑1/PD-L1 ther­a­pies, as iden­ti­fied through tumor expres­sion pro­fil­ing of CD270. 

JJP-1008 blocks the immuno­sup­pres­sive inter­ac­tions of CD270 with inhibito­ry recep­tors CD160 and BTLA, while pre­serv­ing and even enhanc­ing immune acti­va­tion through CD258 (LIGHT). This bal­anced mod­u­la­tion reac­ti­vates the immune system’s abil­i­ty to rec­og­nize and kill can­cer cells, over­com­ing tumor immune evasion. 

Pre­clin­i­cal stud­ies have demon­strat­ed anti-tumor activ­i­ty of JJP-1008 in both in vit­ro and in vivo mod­els, includ­ing melanoma, sup­port­ing its poten­tial as a trans­for­ma­tive check­point inhibitor and poten­tial broad appli­ca­tion in sol­id tumors. The pro­gram is cur­rent­ly advanc­ing through pre­clin­i­cal devel­op­ment, with ongo­ing CMC activ­i­ties sup­port­ing future clin­i­cal translation.

JJP Bio­log­ics is a Pol­ish biotech­nol­o­gy com­pa­ny devel­op­ing nov­el bio­log­ics for the treat­ment of a range of dis­ease indi­ca­tions. We have mul­ti­ple (pre)clinical pro­grams that we plan to devel­op until clin­i­cal proof of con­cept. JJP-1008 is a pio­neer­ing human­ized and sta­bi­lized IgG4‑κ mon­o­clon­al anti­body tar­get­ing CD270. 

High HVEM expres­sion on tumors cor­re­lates with poor prog­no­sis and an immuno­sup­pres­sive tumor microen­vi­ron­ment, mak­ing it an ide­al tar­get for immuno-oncol­o­gy inter­ven­tions. Tumors, includ­ing melanoma, breast, lung and colon can­cers, exploit CD270 sig­nal­ing path­ways to escape immune attack, lead­ing to dis­ease pro­gres­sion and resis­tance to exist­ing immunotherapies. 

Through our deep mech­a­nis­tic insights, we engi­neered JJP-1008 to offer a much-need­ed nov­el treat­ment option for patients who do not respond to cur­rent PD‑1/PD-L1 ther­a­pies, as iden­ti­fied through tumor expres­sion pro­fil­ing of CD270.

JJP-1008 blocks the immuno­sup­pres­sive inter­ac­tions of CD270 with inhibito­ry recep­tors CD160 and BTLA, while pre­serv­ing and even enhanc­ing immune acti­va­tion through CD258 (LIGHT). This bal­anced mod­u­la­tion reac­ti­vates the immune system’s abil­i­ty to rec­og­nize and kill can­cer cells, over­com­ing tumor immune evasion. 

Pre­clin­i­cal stud­ies have demon­strat­ed anti-tumor activ­i­ty of JJP-1008 in both in vit­ro and in vivo mod­els, includ­ing melanoma, sup­port­ing its poten­tial as a trans­for­ma­tive check­point inhibitor and poten­tial broad appli­ca­tion in sol­id tumors. The pro­gram is cur­rent­ly advanc­ing through pre­clin­i­cal devel­op­ment, with ongo­ing CMC activ­i­ties sup­port­ing future clin­i­cal translation.

JJP-1008 as a Novel Checkpoint Inhibitor
JJP-1008 as a Novel Checkpoint Inhibitor
JJP-1008 as a Novel Checkpoint Inhibitor

Aga­ta Drewniak-Maksymów

Aga­ta Drew­ni­ak-Maksymów is a Trans­la­tion­al Sci­ence Lead at JJP Bio­log­ics, spe­cial­iz­ing in oncol­o­gy, immunol­o­gy, and pre­ci­sion med­i­cine. With 10 years of expe­ri­ence in the bio­phar­ma­ceu­ti­cal indus­try, she has held lead­er­ship roles at Sanofi and Kiadis Phar­ma, where she led bio­mark­er and trans­la­tion­al strate­gies across immuno-oncol­o­gy and cell ther­a­py programs. 

Her work focus­es on inte­grat­ing bio­mark­er-dri­ven approach­es to sup­port proof of mech­a­nism, patient selec­tion, and clin­i­cal devel­op­ment. Hold­ing a PhD in Immunol­o­gy from Uni­ver­si­ty of Ams­ter­dam , she is also a lec­tur­er and sci­en­tif­ic con­sul­tant, bridg­ing com­plex sci­ence with clin­i­cal application.

Find out more about JPP Bio­log­ics.

Aga­ta Drew­ni­ak-Maksymów is a Trans­la­tion­al Sci­ence Lead at JJP Bio­log­ics, spe­cial­iz­ing in oncol­o­gy, immunol­o­gy, and pre­ci­sion med­i­cine. With 10 years of expe­ri­ence in the bio­phar­ma­ceu­ti­cal indus­try, she has held lead­er­ship roles at Sanofi and Kiadis Phar­ma, where she led bio­mark­er and trans­la­tion­al strate­gies across immuno-oncol­o­gy and cell ther­a­py programs. 

Her work focus­es on inte­grat­ing bio­mark­er-dri­ven approach­es to sup­port proof of mech­a­nism, patient selec­tion, and clin­i­cal devel­op­ment. Hold­ing a PhD in Immunol­o­gy from Uni­ver­si­ty of Ams­ter­dam , she is also a lec­tur­er and sci­en­tif­ic con­sul­tant, bridg­ing com­plex sci­ence with clin­i­cal application.

profile
Aga­ta Drew­ni­ak-Maksymów, JJP Bio­log­ics, POLAND

Read the Abstracts from Our Invit­ed Speakers

Can­cer Biology

Can­cer Neuroscience

Can­cer Therapy

PORT for Busi­ness — Com­pa­ny Session